Yet in 2019, a joint statement by the American Diabetes Association and the European Association for the Study of Diabetes emphasized that “for patients with type 2 diabetes and established atherosclerotic [cardiovascular] disease ... the level of evidence for MACE benefit is greatest for GLP-1 receptor agonists” [20]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.